meta
|
evidence
oncology
Living systematic review and meta-analysis
muscular invasive bladder cancer (MIBC)
MIBC - (neo)adjuvant (NA)
MIBC - NA - all population
2
MIBC - NA - PDL1 positive
1
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
versus all
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
nivolumab alone
title
placebo
title
CheckMate 274 (PDL1>1%), 2017 NCT02632409 MIBC - NA - PDL1 positive 140/142
Pathology:
MIBC - NA - PDL1 positive;
MIBC - NA - PDL1 positive
CheckMate 274 (PDL1>1%), 2017
nivolumab alone
1
T1
placebo
0
T0